Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) has completed the in-life phase of a 13-week preclinical study on its intranasal foralumab in transgenic HuGEMM CD3 mouse models. The study confirmed that doses up to 50 µg/rodent were well tolerated, with no adverse clinical changes or related fatalities observed. This milestone is crucial for Tiziana as it supports their upcoming FDA Phase 2 meeting request to study foralumab in conditions such as Multiple Sclerosis and Alzheimer’s Disease. Feedback from the FDA is expected in Q1 2023.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) received a 180-day extension from Nasdaq to comply with the minimum bid price rule, now due by June 12, 2023. Initially notified on June 14, 2022, the company had until December 12, 2022, to rectify its bid price deficiency. The extension allows the stock to continue trading on the Nasdaq Capital Market, and compliance can be regained if the stock closes at or above $1.00 per share for ten consecutive business days. Tiziana is focused on developing innovative CNS immunomodulation therapies.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced its 2022 Annual General Meeting scheduled for December 29, 2022. Shareholders must vote by the record date of November 30, 2022. Relevant documents, including the agenda and financial statements, have been sent via mail and are available on the company's website. Tiziana is a clinical-stage biopharmaceutical firm focusing on innovative drug delivery methods for immunotherapy. Its lead candidates include the intranasal foralumab and milciclib, which have shown promising safety and efficacy in clinical studies.

Tiziana Life Sciences (Nasdaq: TLSA) announced that research published in Frontiers in Immunology supports its intranasal foralumab as a promising treatment for autoimmune and CNS diseases. Conducted by Brigham and Women's Hospital and Harvard Medical School, the study involving 27 volunteers demonstrated a favorable safety profile with no adverse events across doses of 10ug, 50ug, and 250ug. Notably, immunological effects peaked at the 50ug dosage, showing potential for future clinical applications without the side effects common in IV anti-CD3 treatments.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced a corporate update focusing on the development of intranasal foralumab for CNS inflammatory diseases. The company aims to prioritize resources for this therapeutic candidate, leveraging positive preclinical results. Upcoming milestones include results from PET scans for patients with non-active secondary-progressive Multiple Sclerosis expected in Q1 2023, and plans for an FDA Type C meeting regarding its Phase 2 program. Tiziana has sufficient capital to fund developments until Q1 2024.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA), a clinical-stage biotechnology company, announced an investor call and webcast scheduled for November 10, 2022, at 10 a.m. ET. This session will provide insights into their innovative immunomodulation therapies utilizing novel drug delivery methods. Tiziana's leading candidates include intranasal foralumab and milciclib, both showing promising safety profiles and clinical responses. The company focuses on alternative routes for immunotherapy, aiming to enhance efficacy and safety compared to traditional IV delivery.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 7,000 common shares at $0.69 each. With this transaction, Cerrone's overall interest in Tiziana remains significant at 37.70%. Tiziana focuses on innovative drug delivery technologies for immunotherapies, including its lead candidates: intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor. These candidates are showing favorable safety profiles and responses in clinical studies.

Tiziana Life Sciences (Nasdaq: TLSA) has completed enrollment of the first patient cohort (n=4) in its Expanded Access Program for foralumab, a treatment for non-active Secondary Progressive Multiple Sclerosis (SPMS). Conducted at Brigham and Women’s Hospital, the program assesses two dosing levels: 50 mcg and 100 mcg. This initiative follows positive feedback from investigators and aims to validate the clinical benefits of foralumab, with results from initial PET scans expected soon, potentially paving the way for Phase 2 studies in the coming year.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced the enrollment of its first patient cohort in an Expanded Access Program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis (SPMS) patients. This program includes two cohorts of four patients each, testing standard and higher dosing of foralumab. Conducted at Brigham and Women’s Hospital, the study aims to assess the clinical benefits of intranasal foralumab, with PET scans for initial patients scheduled in the coming months, supporting a Phase 2 study expected to begin in mid-to-late 2023.